Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome




 Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the Treatment of Carcinoid Syndrome


May 31, 2016


Read the press release >

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022